[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer)
Rhea-AI Filing Summary
Satellos Bioscience reported six-month interim data from TRAILHEAD, an open-label Phase 2 study of SAT-3247 in four adults with Duchenne muscular dystrophy. MRI muscle fat fraction improved on average from 49.7% at baseline to 46.0% at month 6, a 3.7% absolute reduction. Mean total effort (TE99C) rose about 34%, from 16.1 joules/kg in the prior CL-101 study to 21.6 at month 6, while upper extremity strength measures, including handgrip, remained stable after a near-doubling seen in CL-101. Mean creatine kinase declined 38% from 2130 u/l to 1315 u/l. SAT-3247 was well tolerated with no serious treatment-emergent adverse events, no discontinuations, 100% compliance and about 186 days of mean exposure. Patient-reported fatigue (PedsQL-MFS) improved by 6.94 points, and Performance of the Upper Limb 2.0 scores were stable or slightly better. Satellos reiterates plans to complete BASECAMP pediatric enrollment and initiate U.S. TRAILHEAD sites in Q3 2026, with BASECAMP topline and TRAILHEAD 12‑month readouts expected in Q4 2026.
Positive
- None.
Negative
- None.
Insights
Early six-month SAT-3247 data in a small adult DMD cohort show consistent biomarker and functional stability with a clean safety profile.
The update covers four adults with Duchenne muscular dystrophy treated with SAT-3247 for about 186 days. All showed MRI fat-fraction reductions (mean 49.7% to 46.0%), increased TE99C effort (~34% gain), and a 38% decline in mean creatine kinase from 2130 u/l to 1315 u/l. Strength measures, including previously near-doubled handgrip, remained stable.
Safety appears favorable so far, with no serious treatment-emergent adverse events, no discontinuations and 100% compliance. Given only four participants and open-label design, these findings are exploratory but directionally supportive of SAT-3247’s biological activity in advanced DMD.
The company highlights upcoming milestones: completing pediatric BASECAMP enrollment and initiating U.S. TRAILHEAD sites in Q3 2026, followed by BASECAMP topline and a 12‑month TRAILHEAD readout in Q4 2026. Those later datasets will be more informative for assessing clinical impact.
FAQ
What did Satellos (MSLE) report in its six-month TRAILHEAD DMD interim data?
How did SAT-3247 affect muscle fat fraction and effort in Satellos’ TRAILHEAD study?
What safety results did Satellos (MSLE) observe with SAT-3247 in adults with DMD?
How did SAT-3247 impact creatine kinase and patient-reported outcomes in TRAILHEAD?
What are the next clinical milestones for Satellos’ SAT-3247 BASECAMP and TRAILHEAD trials?
How is the TRAILHEAD adult study of SAT-3247 in DMD designed?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-43107
SATELLOS BIOSCIENCE INC.
(Translation of registrant's name into English)
15 Allstate Parkway, Suite 600, Markham,
Ontario, Canada L3R 5B4
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
| Exhibit | Description | |||
| 99.1 | Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 | |||
| 99.2 | Investor Call Presentation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SATELLOS BIOSCIENCE INC. | ||
| (Registrant) | ||
| Date: July 8, 2026 | /s/ Elizabeth Williams, CPA, CA | |
| Elizabeth Williams, CPA, CA | ||
| Chief Financial Officer | ||
EXHIBIT 99.1
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
- All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition
- All four participants showed an increase in TE99C, a measure of maximum effort in upper limbs, with a mean improvement of approximately 34% from a baseline of 16.1 joules/kg to 21.6 joules/kg at TRAILHEAD month 6, suggesting enhanced upper limb activity
- Near doubling of handgrip strength measured during the 28-day CL-101 study maintained through month 6 of TRAILHEAD
- Mean creatine kinase (CK), a biomarker of muscle damage, declined 38% from baseline through month 6 of TRAILHEAD
- Safety profile of SAT-3247 remained favorable and consistent with results previously reported by the Company
- Company to host conference call and webcast today, July 8 at 8:30 a.m. ET
TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced six-month interim data from TRAILHEAD evaluating its investigational drug candidate SAT-3247 in adults living with Duchenne muscular dystrophy ("Duchenne" or "DMD").
The results, in four adults aged 21-28 who had previously completed the Phase 1a/b CL-101 study, showed reduced muscle fat fraction, increased total effort, stable strength, lower CK, and a safety and tolerability profile consistent with previously reported data.
“Adults living with DMD represent one of the most challenging populations in which to evaluate treatment effects because of advanced muscle loss, fat infiltration, and reduced muscle stem cell reserves. Despite meaningful advances with exon-skipping therapies and gene therapy, DMD remains a disease for which there is no cure,” stated Dr. Perry Shieh, Professor of Neurology and Pediatrics at the David Geffen School of Medicine at UCLA. “Adults living with DMD continue to experience progressive muscle loss, making improvement in fat fraction and total effort promising, and stability across multiple clinically relevant measures as observed with SAT-3247 treatment makes these findings potentially clinically meaningful. Although the study is small, the consistency across measures of strength, muscle composition, effort, quality of life and safety is highly encouraging for the ongoing clinical evaluation of SAT-3247 in TRAILHEAD and BASECAMP.”
Data Highlights:
- SAT-3247 was well tolerated; the safety profile was consistent with previously reported data, with no serious treatment emergent adverse events (TEAEs), no TEAEs leading to withdrawal or discontinuation, and 100% compliance over an average of 186 days of drug exposure.
- All four participants showed a decline in muscle fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition.
- All four participants showed an increase in TE99C, a measure of maximum effort in the upper limbs assessed using SYSNAV Syde®, a wearable device widely used in clinical trials to track patient movement in real-world settings, with a mean improvement of approximately 34% from a CL-101 baseline of 16.1 joules/kg to 21.6 joules/kg at TRAILHEAD month 6, suggesting enhanced upper limb activity.
- Across all measures of upper extremity strength (muscle force), including handgrip and handheld dynamometry of the elbow and shoulder, participants demonstrated stability through the end of six months of treatment; for clarity, the near-doubling of handgrip strength reported during the 28-day CL-101 study was maintained through to the end of month 6 of the TRAILHEAD follow-up period.
“We are excited by the six-month interim TRAILHEAD data showing consistent stability or improvement across multiple clinically relevant measures following SAT-3247 treatment in adults living with DMD,” said Frank Gleeson, co-founder and chief executive officer of Satellos. “We believe these findings continue to show the biological activity of SAT-3247 and are potentially encouraging for BASECAMP, where a pediatric DMD population with greater remaining muscle mass may offer additional opportunity to demonstrate the clinical potential of SAT-3247. We remain on track to complete enrollment in BASECAMP and to initiate US clinical trial sites for TRAILHEAD in the third quarter of this year.”
Additional supporting measures:
- Mean CK declined 38% from CL-101 baseline (2130 u/l) through month 6 in TRAILHEAD (1315 u/l).
- Mean PUL2.0 (Performance of the Upper Limb 2.0) increased by one point in two participants and remained stable in two participants from TRAILHEAD baseline through month 6. In the natural history of DMD, upper limb function is generally expected to decline over time.
- Mean PedsQL-MFS scores, a patient reported quality-of-life measure designed to quantify fatigue and adapted for adults, increased 6.94 points from CL-101 baseline (71.53 pts.) to month 6 in TRAILHEAD (78.47 pts.).
Conference Call and Webcast Information
Satellos management will host a conference call and webcast today, July 8 at 8:30 a.m. ET to review the data in more detail.
To access the conference call, interested parties should use the following dial-in information:
| Domestic: | 1-877-269-7751 |
| International: | 1-201-389-0908 |
| Conference ID: | 13761409 |
The presentation will also be available via live webcast here or on the Events and Presentations page of the Investors section of the Company’s website. A replay will be available following the presentation.
ABOUT TRAILHEAD
The TRAILHEAD study is expected to enroll up to 30 male participants in Australia and the United States aged ≥16 years with a definitive diagnosis of DMD and a confirmed mutation in the DMD gene. Participants will receive SAT-3247 at a dose of 60 mg administered orally using a 5-days-on/2-days-off (weekday) dosing regimen for up to 12 months. This study will be conducted at multiple sites in Australia and the United States.
The primary objectives include evaluation of long-term safety and tolerability of SAT-3247, as well as changes in fat fraction of the biceps brachii muscle measured by magnetic resonance imaging (MRI) following 12 months of treatment. Key secondary and exploratory objectives include quantitative assessments of muscle composition via MRI, muscle force by dynamometry, physical activity and function via limb sensors and PUL 2.0, pulmonary function, participant and caregiver quality of life, health economic impact, and proteomic biomarkers.
For additional information: NCT06867107.
ABOUT BASECAMP
BASECAMP is a global, Phase 2, randomized, double-blind, placebo-controlled, proof-of-concept clinical study evaluating SAT-3247 in ambulatory boys with DMD aged 7 to 9 years. The study includes an initial 12-week randomized, double-blind, placebo-controlled treatment period, followed by a 36-week active-treatment period in which all participants receive SAT-3247. The primary objectives are to evaluate the safety and tolerability of SAT-3247, along with its effects on muscle function using standardized dynamometry-based assessments of muscle force. Secondary and exploratory endpoints include assessments of muscle quality, functional outcomes, and biomarkers of muscle regeneration, including Satellos' proprietary Regenerative Index.
BASECAMP is being conducted across multiple clinical sites in North America, Europe, the United Kingdom, and other international regions, and is designed to provide proof-of-concept data supporting the potential of SAT-3247 as a potentially disease-modifying therapy for Duchenne muscular dystrophy.
ABOUT SAT-3247
SAT-3247 is an investigational, proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in DMD and other degenerative muscle diseases or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD that is independent of dystrophin regardless of exon mutation status, with ongoing Phase 2 clinical studies, including TRAILHEAD, an open-label study in adult participants, and BASECAMP, a global, randomized, placebo-controlled study in pediatric participants.
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company advancing SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to enhance the body’s natural muscle repair and regeneration process in degenerative muscle diseases. SAT-3247 is being evaluated as a potentially disease-modifying treatment, initially for DMD, in two Phase 2 clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a protein that is a key regulator of the body’s natural muscle repair and regeneration biology, which Satellos discovered is disrupted in DMD and other degenerative conditions. By inhibiting AAK1, SAT-3247 is designed to re-establish a critical biochemical signal needed to guide this process, in a dystrophin-independent manner. This mechanistic feature offers SAT-3247 the potential for broad applicability as either a stand-alone treatment to potentially enhance muscle and function, or as adjunctive therapy alongside other approaches. Satellos has identified additional degenerative muscle diseases where enhancing muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.
NOTICE ON FORWARD-LOOKING STATEMENTS
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials, including the BASECAMP and TRAILHEAD studies and the expected timing of enrollment and data; the potential of Satellos’ approach in other degenerative muscle diseases and its plans to pursue those opportunities; SAT-3247’s prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: its ability to obtain future funding on favorable terms, if at all; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 27, 2026 (which is located on Satellos’ profile at www.sedarplus.ca) and in Satellos’ public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
CONTACTS
Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com
EXHIBIT 99.2
I N VEST O R C A LL Six - Month TRAILHEAD Data Update Reduced muscle fat fraction, increased total effort, stable strength and favorable safety profile following treatment with SAT - 3247 July 8, 2026 · NASDAQ: MSLE · TSX: MSCL R E GE NE RAT IN G M USCLE F ROM W ITHIN
© 2026 Satellos Bioscience Legal Disclaimers This presentation includes forward - looking information or forward - looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the anticipated benefits to patients from a small molecule treatment for Duchenne ; the advancement SAT - 3247 through clinical trials, including the BASECAMP and TRAILHEAD studies and the expected timing of enrollment and data ; the potential of Satellos’ approach in other degenerative muscle diseases and its plans to pursue those opportunities ; SAT - 3247 ’s prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally ; and Satellos’ technologies and drug development plans . All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward - looking information or statements . ” Often, but not always, forward - looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved . Such statements are based on the current expectations and views of future events of the management of Satellos . These statements are based on assumptions and subject to risks and uncertainties . In making forward - looking statements, Satellos has relied on various assumptions, including, but not limited to : its ability to obtain future funding on favorable terms, if at all ; obtaining positive results in its clinical trials ; its ability to obtain necessary regulatory approvals ; its ability to arrange for the manufacturing of its product candidates and technologies ; and general business, market and economic conditions . Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect . The forward - looking events and circumstances discussed in this presentation, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting Satellos, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of Satellos generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 27 , 2026 (which is located on Satellos’ profile at www . sedarplus . ca) and in Satellos’ public filings on SEDAR+ (sedarplus . ca) and EDGAR (sec . gov) . Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward - looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended . Accordingly, readers should not place undue reliance on any forward - looking statements or information . No forward - looking statement can be guaranteed . Except as required by applicable securities laws, forward - looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward - looking statement, whether resulting from new information, future events, or otherwise . Information herein is subject to change without notice and is based on publicly available information, internally developed data and other sources . Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only . No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information . The public disclosure records of Satellos are expressly not incorporated by reference into this presentation . Satellos disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it . The industry data, forecasts and other information prepared by third parties presented in this presentation, except where otherwise noted, has been compiled from industry sources and participants which, although not independently verified by Satellos, are considered by Satellos to be reliable sources of information . References in this presentation to reports or articles should not be construed as depicting the complete findings of the entire referenced report or article and such report or article is expressly not incorporated by reference into this presentation . Satellos makes no representation or warranty as to the accuracy or completeness of any data or information prepared by third parties included in this presentation and Satellos assumes no liability whatsoever relating to or resulting from such data or information or the use thereof, errors therein or omissions therefrom . 2 RE G E NE R A TI N G M US CL E FRO M W ITHIN
© 2026 Satellos Bioscience CL I NI CA L P RO G RA M TRAILHEAD: Open - Label Study in Adults with Duchenne D ESI G N Population Adult males ≥16 years of age with confirmed DMD diagnosis and confirmed mutation in DMD gene; up to 30 expected to be enrolled (Australia & U.S.) Dose SAT - 3247 60 mg oral, 5 - days - on / 2 - days - off, for up to 12 months Primary endpoints Long - term safety & tolerability; biceps brachii fat fraction by MRI at 12 months Other endpoints Muscle composition (MRI), muscle force (dynamometry), physical activity and function (PUL2.0, sensors), pulmonary, QoL, health economic impact, proteomics T H I S R EAD O U T 4 adults who completed CL - 101 21 – 28 years of age 186 days mean drug exposure 100% compliance 3 RE G E NE R A TI N G M US CL E FRO M W ITHIN SAT - 3247 is an investigational agent not yet approved in any country or region
© 2026 Satellos Bioscience 6 - M O NT H RE A DO UT A Consistent Picture of Stable or Improving Outcomes Six - month findings in four adults (aged 21 – 28) with Duchenne who originally enrolled in CL - 101 — one of the most challenging populations in which to show treatment effects. −3.7% MRI muscle fat fraction — reduced in all four participants +~34% Total effort (TE99C) — increased in all four participants ~2 î Handgrip near - doubling during CL - 101 maintained KEY TAKEAWAY Across muscle composition, effort, strength, and safety, demonstrated outcomes were stable or improving through six months of SAT - 3247 treatment. Favorable Safety profile — no serious treatment - emergent adverse events (TEAEs), 100% compliance 4 RE G E NE R A TI N G M US CL E FRO M W ITHIN SAT - 3247 is an investigational agent not yet approved in any country or region
© 2026 Satellos Bioscience S A FE TY & TO LE R A B I LI TY SAT - 3247 Well Tolerated; Favorable Safety Profile Maintained Through Six Months 0 serious TEAEs 0 TEAEs leading to withdrawal or discontinuation 100% treatment compliance 186 days mean drug exposure KEY TAKEAWAY No serious or treatment - limiting safety signals were observed — supporting continued clinical evaluation of SAT - 3247. 5 RE G E NE R A TI N G M US CL E FRO M W ITHIN SAT - 3247 is an investigational agent not yet approved in any country or region *Data as of 18 May 2026
© 2026 Satellos Bioscience M U S C L E C OM P OS IT ION MRI Muscle Fat - Fraction Improved in All Participants Mean Changes - 3.7 0 - 1 - 2 - 3 - 4 - 5 - 6 - 7 Dixon (%) Mean Change (% “ SD) Individual participants Natural History of Elbow Flexor Fat - Fraction 1 Individual Values and Changes Muscle MRI Fat Fraction (%) Change Month 5 Baseline - 6.2% 75.3% 81.4% Participant 1 - 0.9% 34.4% 35.3% Participant 2 - 5.8% 22.1% 27.9% Participant 3 - 1.9% 52.2% 54.1% Participant 4 - 3.7 “ 2.7% 46.0 “ 23.1% 49.7 “ 23.9% Mean “ SD CL - 101 and TRAILHEAD ages TRAILHEAD Baseline FF 1 Naarding KJ, et al. Neurology 2021. 97:e1737 - e1742 Elbow flexor muscles included biceps and brachialis muscles Improvement KEY TAKEAWAY Muscle fat fraction showed a decrease in every participant, compared with a 5.9% 1 annual increase reported in natural history studies. 6 RE G E NE R A TI N G M US CL E FRO M W ITHIN SAT - 3247 is an investigational agent not yet approved in any country or region
© 2026 Satellos Bioscience R E AL - W O RL D F UNCT I O N Total Effort (TE99C) Improved Over Six Months +~34% From mean 16.1 joules/kg at baseline to 21.6 at month 6; increases observed in all four participants TE99C (99th - percentile total effort) is captured continuously at home by the SYSNAV Syde® medical - grade wearable KEY TAKEAWAY Demonstrated increase in maximum effort in every participant — an emerging real - world activity signal that complements the imaging and strength findings. Total Effort (99 th Percentile) Change from CL - 101 Baseline 5.47 0 2 4 6 8 10 12 14 Change from Baseline (J/kg “ SD) Mean Change Individual participants Improvement 7 RE G E NE R A TI N G M US CL E FRO M W ITHIN SAT - 3247 is an investigational agent not yet approved in any country or region
© 2026 Satellos Bioscience M US CL E S T RE NG T H Upper - Extremity Strength Maintained S T ABL E ACRO S S AL L M US CL E G RO UP S ✓ Handgrip ض Elbow ✓ Shoulder KEY TAKEAWAY Strength demonstrated stability across every measure, with previously reported near - doubling handgrip strength preserved, not the decline expected in untreated adults. Time off SAT - 3247: 7 - 11 months The near - doubling of handgrip strength seen in the 28 - day CL - 101 study was maintained through six months of TRAILHEAD follow - up. Handgrip Strength CL - 1 01 T R AI L H E AD SAT - 3247 is an investigational agent not yet approved in any country or region 8 RE G E NE R A TI N G M US CL E FRO M W ITHIN
© 2026 Satellos Bioscience BI O M A RKE RS CK levels in TRAILHEAD are lower than those observed in CL - 101 After 28 days in CL - 101 , an interval of 7 - 11 months, and 140 days in TRAILHEAD SAT - 3247 is an investigational agent not yet approved in any country or region Serum CK Mean Serum Creatine Kinase (CK) Concentrations Demonstrated 38% Decline Mean CK declined 38% from CL - 101 baseline (2130 u/l) through month 6 in TRAILHEAD (1315 u/l). Time off SAT - 3247: 7 - 11 months 9 RE G E NE R A TI N G M US CL E FRO M W ITHIN
© 2026 Satellos Bioscience F U N C T I O N A L A SSESSM EN T S Performance of Upper Limb (PUL 2.0) Function Maintained 2 participants improved by 1 point 2 participants remained stable KEY TAKEAWAY In the natural history of DMD, PUL2.0 function is generally expected to decline over time. 1 SAT - 3247 is an investigational agent not yet approved in any country or region TRAILHEAD Baseline TRAILHEAD Day 140 10 RE G E NE R A TI N G M US CL E FRO M W ITHIN PUL 2.0 1 Pane M, et al. J Neuromuscul Dis. 2023. 21.8 22.3
© 2026 Satellos Bioscience PA T I EN T - RE P O RT E D O UT CO M E S Patient Reported Quality - of - life Measure (PedsQL) Scores Demonstrated Improvement 71.53 78.47 0 10 20 30 40 50 60 70 100 90 80 Mean PedsQL Mean Total Score (score “ SD) CL - 101 Baseline TRAILHEAD Day 140 +6.94 Mean PedsQL - MFS scores increased (CL - 101 baseline → month 6 in TRAILHEAD) 11 RE G E NE R A TI N G M US CL E FRO M W ITHIN PedsQL designed to quantify fatigue and adapted for adults SAT - 3247 is an investigational agent not yet approved in any country or region
© 2026 Satellos Bioscience “ Adults living with DMD continue to experience progressive muscle loss, making improvement in fat fraction and total effort promising, and stability across multiple clinically relevant measures as observed with SAT - 3247 treatment makes these findings potentially clinically meaningful. Although the study is small, the consistency across measures of strength, muscle composition, effort, quality of life and safety is highly encouraging for the ongoing clinical evaluation of SAT - 3247 in TRAILHEAD and BASECAMP. Perry Shieh, MD, PhD, FAAN · Professor of Neurology and Pediatrics, David Geffen School of Medicine at UCLA 12 RE G E NE R A TI N G M US CL E FRO M W ITHIN
© 2026 Satellos Bioscience P A T H F O RW A RD Encouraging for BASECAMP — Upcoming Catalysts “We believe these findings continue to show the biological activity of SAT - 3247…potentially encouraging for BASECAMP, where a pediatric DMD population with greater remaining muscle mass may offer additional opportunity to demonstrate the clinical potential of SAT - 3247.” — Frank Gleeson, Co - Founder & CEO Q3 2026 Expected to complete BASECAMP enrollment; expected to initiate U.S. clinical sites for TRAILHEAD Q4 2026 BASECAMP topline data expected — pediatric proof - of - concept and key value inflection Q4 2026 TRAILHEAD 12 - month primary readout expected; potential FDA engagement on a path forward subject to 12 - month data KEY TAKEAWAY A differentiated, dystrophin - independent mechanism with clear near - term catalysts — anticipate completing BASECAMP enrollment and initiating U.S. TRAILHEAD sites in Q3 2026. 13 RE G E NE R A TI N G M US CL E FRO M W ITHIN
RE G E NE R A TI N G M US CL E FRO M W ITHIN © 2026 Satellos Bioscience THE RO A D A HE A D Reimagine how Duchenne muscular dystrophy is treated Regenerate muscle with an oral, once - daily medicine Realize a new future for patients and families